8 news items
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
EXAS
24 May 24
and ethnic groups. The first study confirmed that the test is prognostic for breast cancer-specific mortality and predictive of chemotherapy benefit
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
ABNB
AKAM
APP
9 May 24
benefits rose from 209,000 to 231,000 in the week ending May 4, surpassing market expectations of 210,000 and reaching
Wall Street Stares At Weaker Open On Rate Anxiety, Hopes For Better Earnings: Analyst Pencils Key S&P 500 Support Level
ABNB
AKAM
AMC
9 May 24
, on average, expect the number of individuals claiming unemployment benefits to come in at 214,000 in the week ended May 4, up from 208,000
Exact Sciences Announces First-Quarter 2024 Results
EXAS
8 May 24
Score® test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast
Exact Sciences To Present Late-Breaking Data From ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test At AACR Annual Meeting 2024
EXAS
8 Apr 24
confirms that our multi-biomarker class approach to MCED test design may deliver benefits beyond what is currently achievable. The sensitivity
yc23iztx
EXAS
8 Apr 24
-biomarker class approach to MCED test design may deliver benefits beyond what is currently achievable. The sensitivity and specificity achieved
2w5uohx5p5tzvmo2tu7jhs0pjupfav 1xc13mfdlohdgt
EXAS
4 Apr 24
to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX Breast Recurrence Score test is recognized
z0gcs rld
EXAS
28 Mar 24
the development and commercialization of the Oncoguard Esophagus test; the performance characteristics and healthcare benefits of the Oncoguard Esophagus test
- Prev
- 1
- Next